|
|
 | | | |
- close
- close
- close
- close
Oncolytics Biotech (ONCY) |
StreetInsider.com
May 9
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Oncolytics+Biotech+%28ONCY%29+Posts+Q1+Loss+of+8cShare/8320336.html for the full story.
TheStreet.com
Apr 5
Comment
BOSTON (TheStreet) -- This week's Biotech Stock Mailbag opens with a tweet from eliasinthezone: "AF, what do you think about $MNKD? I hear a lot of good things but I haven't read yet an article from you on this stock."
The last time I wrote...
StreetInsider.com
Mar 28
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Oncolytics+%28ONCY%29+REOLYSIN+Met+Primary+Endpoint+in+Phase+2+on+SCCLC/8216741.html for the full story.
StreetInsider.com
Mar 5
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Oncolytics+%28ONCY%29+Completes+Enrollment+in+REOLYSIN+Phase+2/8155035.html for the full story.
Benzinga
Mar 4
Comment
Analysts at Piper Jaffray initiated coverage on shares of Oncolytics Biotech (NASDAQ: ONCY) with an “overweight” rating. The target price range for Oncolytics Biotech is set to $6. Oncolytics Biotech's shares closed at $3.36 on Friday....
Benzinga
Feb 25
Comment
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced today that it has closed its previously
announced underwritten public offering of 8.0 million common shares, at a
public offering price of US$4.00 per common share. The aggregate gross
proceeds...
StreetInsider.com
Feb 20
Comment
Chelsea Therapeutics (Nasdaq: CHTP) 83% HIGHER; received written guidance from the Director of the Office of New Drugs ("the Director") at the U.S. Food and Drug Administration (FDA) stating that Study 306B has the potential to serve as the basis...
StreetInsider.com
Feb 20
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Oncolytics+Biotech+%28ONCY%29+Prices+8M+Shares+at+%244+%28Halted%29/8115005.html for the full story.
StreetInsider.com
Feb 19
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Oncolytics+Biotech+%28ONCY%29+to+Offer+Common+Stock/8112232.html for the full story.
FierceBiotech
Feb 8
Comment
Oncolytics Biotech ($ONCY) has generated more upbeat data from an anticancer virus program. This morning the Calgary-based biotech reported tumor shrinkage in 95% of patients analyzed who took its experimental anticancer virus and a pair of...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
